promising results

Bobak Azamian PhD MD Tarsus CEO
Biotech

Tarsus eyes FDA filing in 2022 for eyelid mange eye drop

Tarsus Pharmaceuticals met all primary and secondary endpoints on its eyedrop treatment for Demodex blepharitis in a phase 2b/3 trial
Kyle LaHucik Jun 21, 2021 6:05am
Roche

Interim look at data shows Roche hemophilia A drug cuts bleeds

Apr 17, 2017 8:30am